Literature DB >> 2867486

Pupillary effects of neurotensin: structure-activity relationships.

D E Hernandez, K B Simons, D Spampinato, F Rioux, S St-Pierre.   

Abstract

We have previously reported that intracameral (I.C.) administration of neurotensin (NT) potently induces a time- and dose-dependent miosis in rabbits. This study was designed to determine structure-function relationships for NT-induced miosis. NT and twelve different fragments and analogs of NT, and the structurally-unrelated peptides beta-endorphin (beta-end), somatostatin (SRIF) and thyrotropin-releasing hormone (TRH) were tested in a dose equimolar to 30 micrograms of NT for their effects on pupillary diameter (PD) in rabbits. In confirmation of previous findings, NT produced significant miosis. Followed in order of duration of effect were D-Trp11-NT, D-Tyr11-NT, the N-terminal fragment NT1-12, [Gln4] - NT and NMe-NT. The N-terminal fragment NT1-8, D-Arg8-NT, and D-Phe11-NT were weakly active. In addition, the initial N-terminal fragment NT1-6 and the C-terminal fragments NT8-13 and NT9-13 did not affect PD. D-Pro10-NT, beta-end, SRIF, and TRH were totally ineffective. The results of this investigation contribute to support a role for NT on regulation of pupillary function, and suggest that the midportion of NT appears to be critical for the expression of NT-induced miosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2867486     DOI: 10.1016/0143-4179(85)90119-2

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  2 in total

1.  Immunohistochemical demonstration of neurotensin and tyrosine hydroxylase in iris nerves of the rabbit eye.

Authors:  D E Hernandez; L Jennes
Journal:  Histochemistry       Date:  1989

2.  Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer.

Authors:  I Sehgal; S Powers; B Huntley; G Powis; M Pittelkow; N J Maihle
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.